Novartis Wins Second Landmark German Case, This Time For Probiotics
Executive Summary
Following a landmark win against the German government for the Rx-to-OTC switch of desloratadine last month, Novartis has again secured a victory in the German Higher Court system, this time to continue marketing its Biosan probiotics range in the country.
You may also be interested in...
Novartis Seeks 'Amicable' Resolution Of German Probiotics Dispute
Novartis is in discussion via its Hexal subsidiary with Germany's Association for Social Competition (VSW) over whether it must withdraw its Biosan range of probiotic supplements currently on the German market following a recent Higher Regional Court ruling.
German Wellness Market News: Dr Loges Ignores EU CBD Rules, Three ‘Noo’ Brain Health Supplements
A new CBD oil from Dr Loges, three ‘nootropic’ brain health supplements from Dr Loges, Hevert and Pure Encapsulations and a magnesium supplement from Stada feature in this month’s German wellness market round-up.
Novartis Wins Landmark Case Against German Government Over Desloratadine Switch
Generics giant Novartis through its Hexal subsidiary has won an important case against the German Ministry of Health over a delayed prescription-to-OTC switch of desloratadine, which shows European Union Member States have got the authority to switch at a national level centrally authorized drugs.